JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

Strona główna・Stock List・Roivant Sciences Ltd
Search

Roivant Sciences Ltd

Closed

SectorHealthcare

27.83 -2.66

Strong Buy

Price update 1 maj 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

27.83

Max

28.12

Key metrics

By Trading Economics

Income

-200M

-314M

Sales

428K

2M

Profit margin

-15,692.896

Employees

750

EBITDA

-132M

-290M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+24.69% upside

Market Stats

By TradingEconomics

Market Cap

4.7B

20B

Previous open

30.49

Previous close

27.83

News Sentiment

By Acuity

67%

33%

316 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

11 / 11.18 Support & Resistance

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 maj 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Read

4 maj 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Read

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Read

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Read

4 maj 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Read

4 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Read

4 maj 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Read

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Read

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Read

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Read

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

DJ

Read

4 maj 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Read

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Read

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Read

4 maj 2026, 22:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Read

4 maj 2026, 22:26 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Read

4 maj 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Read

4 maj 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Read

4 maj 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Read

4 maj 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Read

4 maj 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Read

4 maj 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Read

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Read

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Read

4 maj 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Read

4 maj 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Read

4 maj 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Read

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

24.69% upside

12 Months Forecast

Average 34.7 USD  24.69%

High 41 USD

Low 29 USD

Based on 10 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Based on 10 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Short Term

Weak Bullish Evidence

Bullish events outweigh bearish events.

Intermediate Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Long Term

Bearish Evidence

There is one bearish event.

Sentiment

By Acuity

316 / 347 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Other stocks from the sector

JNJ

Johnson and Johnson

225.54

↓-0.03%

UNH

UnitedHealth Group Inc

370.35

↑ +1.35%

TMO

Thermo Fisher Scientific Inc

465.79

↓-0.01%

ISRG

Intuitive Surgical Inc

450.79

↓-1.5%

ABT

Abbott Laboratories

86.59

↓-2.53%
help-icon Live chat